Participation terms in the Combined General Meeting
August 8, 2022
MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report
July 29, 2022
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000
July 27, 2022
MedinCell announces its full year financial results April 2021 – March 2022
June 14, 2022
Videoconference and release of fiscal 2021-2022 financial results on June 14, 2022
June 7, 2022
MedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer
May 9, 2022
MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM
May 3, 2022
MedinCell provides additional information regarding the new drug application for mdc-IRM
April 19, 2022
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
April 19, 2022
Publication of the 2022 financial calendar
January 13, 2022
